Hormone Replacement Therapy
Hormone replacement therapy (HRT) is the clinical question that most often surfaces at the interface of ME/CFS and the reproductive axis: as a woman enters perimenopause, should estrogen-based therapy be considered for symptom control, and does it interact with the disease itself? The honest answer, on current evidence, is that HRT benefit in ME/CFS is unproven, while its safety profile is well characterised and route-dependent. This asymmetry — real safety data, absent efficacy data — must govern how HRT is discussed.
Two mechanistic threads connect HRT to ME/CFS. First, if the menopause transition compounds symptoms by withdrawing hormonal vascular, volume, and metabolic support (see Perimenopause, Menopause, and Early Menopause), then replacing that support is a physiologically motivated intervention to test. Second, estrogen and progesterone directly modulate mast cell activity — the estrogen–progesterone–mast-cell axis that links the female predominance of ME/CFS to its MCAS comorbidity — which is a double-edged mechanism: it could be the basis for benefit, or the basis for harm if hormones aggravate mast cell activation in susceptible women (Zaitsu et al. 2007) (Muñoz-Cruz et al. 2015).
Pregnancy and lactation: HRT is contraindicated during pregnancy (estrogen-containing therapy is not used in pregnancy) and is not the intended treatment population, which is peri/post-menopausal women. HRT is not a lactation-management therapy; breastfeeding women who need menopausal-symptom management should consult specialist guidance. No HRT-in-pregnancy safety data are relevant here because HRT is not prescribed in pregnancy.
Drug interactions: HRT (estrogen) can interact with a number of medications relevant to ME/CFS care, including thyroid hormone replacement (estrogen raises thyroxine-binding globulin, potentially requiring a thyroid-dose adjustment), and can alter the metabolism of some anticonvulsants and corticosteroids. A targeted drug-interaction search against the standard ME/CFS co-prescription list (fludrocortisone, midodrine, low-dose naltrexone, pyridostigmine, beta-blockers, antihistamines, gabapentin/pregabalin, trazodone, amitriptyline, NSAIDs, IVIG, rituximab) was not individually performed during this integration; the clinically salient interactions for HRT are those affecting thyroid, corticosteroid, and anticoagulant use, and any HRT decision should be reviewed for drug interactions by the prescribing clinician.
1 HRT Safety and Route of Administration
Before any consideration of HRT for symptom control in ME/CFS, the safety data must be stated plainly, because it constrains the entire discussion. HRT is not a benign supplement; its cardiovascular and venous-thromboembolism (VTE) risk depends strongly on the route and combination used.
A nationwide Swedish register-based emulated target trial of 919,614 women aged 50–58 (77,512 HRT initiators) quantified contemporary HRT risk (Johansson et al. 2024). Oral estrogen-progestin therapy was associated with elevated venous thromboembolism risk (continuous regimen HR 1.61; sequential HR 2.00), oral estrogen-only with VTE risk (HR 1.57), and tibolone with increased ischaemic heart disease, cerebral infarction, and myocardial infarction risk (though not VTE). These are the most current, large-scale harm data for contemporary HRT regimens.
The clinical corollary — supported by systematic review — is that transdermal estrogen carries a lower VTE risk than oral estrogen, because it avoids first-pass hepatic metabolism and the associated pro-coagulant effects (Goldštajn et al. 2023). This makes route of administration a central safety decision.
Evidence type: nationwide emulated target trial (n=919,614, BMJ) + systematic review. Certainty: 0.64 (Johansson, discounted; general population weight 0.75, raw 0.85) and 0.49 (Goldstajn, discounted).
Consequence: When HRT is discussed with an ME/CFS patient, the safety conversation is not “is HRT safe” but “which route and regimen” — transdermal estrogen is the lower-VTE-risk choice, and the cardiovascular risk profile differs by regimen. These are actionable, well-evidenced safety facts that should frame any efficacy discussion.
Severity applicability: HRT safety data derive from the general menopausal population and are not ME/CFS-severity-specific; VTE risk considerations are relevant across severities but are particularly consequential for bedbound patients (immobility is an independent VTE risk factor). For bedbound or very-severe patients specifically, the risk/benefit calculus shifts: oral estrogen (with its higher VTE risk) is the least desirable route, transdermal estrogen carries the lower-VTE option, and the decision should weigh the independent VTE contribution of immobility alongside the usual menopausal-indication benefit. This is a graded clinical caution — not a blanket contraindication, and not a recommendation to forgo HRT for its established menopausal indications.
2 The Estrogen–Progesterone–Mast-Cell Axis
A central mechanistic thread connecting female predominance, MCAS comorbidity, and the reproductive axis is the direct action of estradiol and progesterone on mast cells. Because HRT changes circulating estrogen and progesterone, understanding this axis is essential to predicting both potential benefit and potential harm.
A body of in-vitro and animal work establishes that female sex steroids directly regulate mast cell behaviour. Estradiol can sensitise or prime mast cells toward activation and degranulation, while progesterone has a more complex, often suppressive, modulatory role (Zaitsu et al. 2007) (Muñoz-Cruz et al. 2015) (Jensen et al. 2010). Environmental estrogens similarly modulate mast cell function, and the ovariectomised-mouse model demonstrates the effect of ovarian-hormone withdrawal on mast cell responses (Narita et al. 2007) (Jensen et al. 2010).
This is the plausible mechanistic bridge for the clinical epidemiology: it offers a pathway by which estrogen-driven mast cell activation could contribute to the MCAS/POTS/hEDS cluster that disproportionately affects women with ME/CFS, and by which hormonal state (menstrual cycle phase, pregnancy, menopause, HRT) could modulate the mast-cell-dependent symptoms (flushing, histamine-type reactions, pain, fatigue) that are common in ME/CFS.
Certainty: 0.24–0.28 (discounted) — the mast-cell mechanism is established in model systems and replicated across independent groups, but the population weight for in-vitro/animal evidence (0.40–0.50) drives the discounted certainty down. Translation gap: [in-vitro / animal] → human. The direct effect of estradiol/progesterone on mast cells has not been confirmed in ME/CFS patients.
Falsifiable prediction: In women with ME/CFS and comorbid MCAS symptoms, hormonal-state-dependent mast cell mediator release (e.g., serum tryptase or histamine) should vary across the menstrual cycle and change across menopause or with HRT, in a direction consistent with the model-system findings. The hypothesis is falsified if mast cell mediator levels in ME/CFS patients do not track hormonal state.
Consequence: This axis makes hormones a candidate modifiable driver of mast-cell-dependent symptoms — meaning that for some women, managing hormonal state (including, potentially, HRT or its avoidance) could be a lever on the MCAS component of their illness, and it explains why the same hormones that might help one patient could aggravate another.
Because estradiol can prime mast cells toward activation, a mechanistic reading does not license the conclusion that raising estrogen via HRT will help all women with ME/CFS — in a woman whose mast cell activation is estrogen-sensitive, HRT could worsen flushing and histamine-type symptoms. Conversely, in a woman whose mast cell activation is suppressed by progesterone or whose dominant issue is post-menopausal hormonal withdrawal, the same intervention could help. The axis predicts individual variation, not a uniform direction of effect.
Consequence: Any HRT trial or clinical use in ME/CFS should monitor mast-cell-dependent symptoms (flushing, histamine reactions, pain flares) as a possible adverse or benefit signal, and a woman’s MCAS status should be a factor in the risk/benefit discussion — not a blanket contraindication, and not a blank cheque.
Severity applicability: Unknown — the mast-cell mechanism evidence is model-system, not severity-stratified.
The estrogen-mast-cell axis (Estradiol and Progesterone Directly Modulate Mast Cell Activation) and its double-edged warning (Hormonal Influence on Mast Cells Is Double-Edged — Not a Blanket Reason to Use or Avoid HRT) predict that mast-cell reactivity in ME/CFS is individually hormone-sensitive. Yet mast-cell-stabilizer trials (ketotifen, cromolyn) in ME/CFS are analysed without any hormonal covariate. A low-cost, high-value research refinement: stratify existing and future stabilizer-trial data by (a) cycle phase, (b) menopausal status, and (c) the estradiol:progesterone (E2:P4) ratio — the ratio, not absolute levels, is predicted to be the mast-cell-reactivity determinant (high E2 with low P4 = unopposed estradiol priming; high P4 = suppression). If stabilizer efficacy concentrates in high-E2/low-P4 states, it would explain heterogeneous trial results and point to timing stabilizers to the estrogen-dominant window or adding progestogenic suppression. (Origin: brainstorm.)
Certainty: 0.40 — as a re-analysis/trial-design direction with sound mechanistic grounding; the ratio-specific claim itself is untested.
Falsifiable prediction: Re-analysis of an existing mast-cell-stabilizer dataset, or a prospective stabilizer trial in premenopausal ME/CFS women (n ≥ 30, phase-confirmed, E2 and P4 measured), shows ≥30% greater stabilizer benefit in the high-E2/low-P4 (follicular-to-ovulatory) phase than in the high-P4 (luteal) phase or in post-menopausal women. Falsified if stabilizer efficacy is uniform across hormonal states.
Consequence: Mast-cell-stabilizing drugs might — if the hormonal-sensitivity hypothesis holds — work better during certain weeks of the cycle or before menopause, and measuring the estrogen-to-progesterone balance could help design or stratify future trials. This is a research-design implication, not a near-term clinical recommendation: no trial has yet shown hormonal-phase-dependent stabilizer efficacy.
Ch30 cross-reference: The mast-cell-diagnostic use of the menstrual cycle is treated in the mechanistic-cascade chapter’s endogenous-probes section (see menstrual cycle dopaminergic mast cell probe), which covers the cycle as a dopaminergic and mast-cell diagnostic probe. The present section extends that treatment to the estrogen–progesterone–mast-cell axis itself and to its implications for HRT and stabilizer-trial design; the two treatments are complementary and should be read together.
3 HRT in ME/CFS: Unproven Benefit, Real Safety Data
The central honest conclusion about HRT in ME/CFS is that its benefit is untested while its safety is well characterised (see Hormone Replacement Therapy). This asymmetry must be stated without ambiguity, so that patients and clinicians are not misled by the physiological plausibility of benefit into assuming it is established.
There is no randomised controlled trial of HRT in ME/CFS, and no prospective cohort that quantifies whether HRT changes ME/CFS symptom severity. The physiological rationale is real but indirect: HRT replaces the hormonal vascular, volume, and metabolic support whose withdrawal plausibly compounds symptoms at the menopause transition (see A Longitudinal AMH Slope Panel Predicts Early Menopause Before the Event), and the estrogen–progesterone–mast-cell axis provides a plausible mechanistic route (see HRT Cardiovascular and VTE Risk Is Route- and Regimen-Dependent). But rationale is not evidence.
The honest position is therefore: HRT may or may not help ME/CFS symptoms; no data currently support benefit; and the decision to use it should be driven by its established indications (menopausal symptom control, bone health) and its well-characterised safety profile — not by a claim that it treats ME/CFS.
Certainty: n/a — the absence-of-trial is the fact; the efficacy question is genuinely open.
Testable outcome: The efficacy question can only be resolved by the route-stratified trial described in A Route-Stratified HRT Trial in Perimenopausal ME/CFS Is the Decisive Test — HRT would be shown to improve ME/CFS only if a pre-specified fatigue/PEM/orthostatic endpoint shows a clinically meaningful active-versus-placebo difference.
Consequence: A clinician should not tell an ME/CFS patient that HRT “will help her ME/CFS” — there is no evidence for that. HRT is a legitimate consideration for menopausal symptoms on its own merits, with transdermal estrogen as the lower-VTE-risk choice, but any improvement in ME/CFS-specific symptoms would currently be anecdotal rather than demonstrated.
Large cohort analyses confirm that sex and sex-hormone physiology meaningfully shape post-infectious (Long COVID) illness: symptom clusters, prevalence, and presentation differ by sex in ways consistent with hormonal modulation (Shah et al. 2025). This provides population-scale context for why the reproductive axis matters in ME/CFS and for why HRT is a physiologically motivated question. It does not demonstrate that HRT improves ME/CFS.
Evidence type: RECOVER Consortium analysis, large cohort. Certainty: 0.68 (discounted; Long-COVID population weight 0.85, raw 0.80).
Consequence: The sex-hormone framing is credible and worth studying, but a patient asking “will HRT fix my ME/CFS” should hear the truth: the rationale exists, the evidence does not.
Given the safety data favouring transdermal estrogen (Goldštajn et al. 2023) and the mechanistic rationale from the menopause-transition and mast-cell axes, the decisive experiment is a route-stratified, randomised, placebo-controlled trial of transdermal estradiol (± progesterone where a uterus is present) in perimenopausal women with ME/CFS, powered for fatigue, PEM, and orthostatic symptoms, with mast-cell-dependent symptoms and VTE markers as safety outcomes.
This prediction is a research design, not a treatment claim. It is motivated by (a) the real safety asymmetry, (b) the menopause-transition acceleration hypothesis A Longitudinal AMH Slope Panel Predicts Early Menopause Before the Event, and (c) the mast-cell axis HRT Cardiovascular and VTE Risk Is Route- and Regimen-Dependent — but it has not been run.
Falsifiable prediction: In the proposed route-stratified, placebo-controlled trial, transdermal estradiol (± progesterone) should produce a clinically meaningful improvement (≥ 0.4 SD on a pre-specified fatigue or PEM instrument, or ≥ 30% responder-rate difference on a composite fatigue/PEM/orthostatic endpoint) versus placebo, with safety outcomes (mast-cell flare, VTE markers) monitored. The HRT-benefit hypothesis is falsified if the active arm shows no superiority over placebo on the pre-specified fatigue/PEM/orthostatic endpoints, or if the benefit is confined to placebo-responder subgroups.
Consequence: Only such a trial can convert the plausible-but-unproven HRT rationale into evidence. Until then, HRT in ME/CFS remains a question, not an answer — and the research community has a clear, safe, route-aware trial to run.
Severity applicability: An HRT trial would need explicit severity stratification; none of the current evidence is ME/CFS-severity-specific. For bedbound patients, immobility interacts with VTE risk and requires particular caution.
Monitoring parameters: There is no validated ME/CFS-specific monitoring protocol for HRT; standard menopausal-HRT gynaecological follow-up applies. Where HRT is used in a woman with ME/CFS, the mast-cell axis warning (HRT Cardiovascular and VTE Risk Is Route- and Regimen-Dependent) recommends additionally monitoring mast-cell-dependent symptoms (flushing, histamine-type reactions, pain flares) as a possible adverse or benefit signal, alongside the standard VTE and cardiovascular safety monitoring appropriate to the route.
Stopping criteria: HRT use specifically for ME/CFS symptom control is research-stage — there are no ME/CFS-specific clinical stopping criteria established. Standard HRT review criteria (periodic reassessment of continued need, benefit versus risk) apply; and any HRT decision and its continuation should be reviewed by the prescribing clinician, particularly where the indication is menopausal-symptom control rather than a proven ME/CFS effect.